The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells

Cancer Detection and Prevention

Volumn 28, Issue 4, 2004, Pages 283-293

  Głowacka Rogacka, Dorota ^a   Arciemiuk, Małgorzata ^a   Kupiec, Agnieszka ^a   Bontemps Gracz, Maria M ^a   Borowski, Edward ^a   Tarasiuk, Jolanta ^b  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF SZCZECIN   (Poland)

Author keywords

Benzoperimidine esters; Inhibition of active efflux; MRP1 protein; Multidrug resistance; P glycoprotein; Pirarubicin

Indexed keywords

BENZENE DERIVATIVE; ESTER DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PIRARUBICIN; PYRIMIDINE DERIVATIVE;

ARTICLE; BIOACCUMULATION; BIOLOGICAL MONITORING; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG INHIBITION; ENZYMATIC DEGRADATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LATENT PERIOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPECTROFLUOROMETRY;

BENZENE DERIVATIVES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEIN; QUINAZOLINES; TUMOR CELLS, CULTURED;

EID: 12344303029     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2004.02.005     Document Type: Article

References (41)

1. Klein I., Sarkadi B., Váradi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta. 1461:1999;237-262
2. Sauna Z.E., Smith M.M., Müller M., et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomem. 33:2001;481-491
3. Allen J.D., Brinkhuis R.F., van Deemter L., et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 60:2000;5761-5799
4. Savas B., Cole S.P.C., Akoglu T.F., et al. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells. Nat. Immun. 11:1992;177-192
5. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160:1997;161-175
6. König J., Nies A.T., Cui Y., et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specifity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta. 1461:1999;377-394
7. Paulusma C.C., van Geer M.A., Evers R., et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338:1999;393-401
8. Borst P., Evers R., Kool M., et al. A family of drug transporters: the multidrug resistance-associated proteins. J. Nat. Cancer Inst. 92:2000;1295-1302
9. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:2000;265-283
10. Szabó D., Keyzer H., Kaiser H.E., et al. Reversal of multidrug resistance of tumor cells. Anticancer Res. 20:2000;4261-4274
11. Michieli M., Damiani D., Michelutti A., et al. P170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporine A derivatives. Haematologica. 79:1994;119-126
12. Lampidis T.J., Krishan A., Planas L., et al. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Delivery. 3:1986;251-259
13. Plumb J.A., Milroy R., Kaye S.B. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem. Pharmacol. 3:1990;251-259
14. 4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 271:1996;9675-9682
15. 4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem. Biophys. Res. Commun. 251:1998;307-312
16. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 67:1989;17-28
17. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 208:1995;345-352
18. Sumizawa T., Chen Z.S., Chuman Y., et al. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol. Pharmacol. 51:1997;399-405
19. Stefanska B., Dzieduszycka M., Bontemps-Gracz M.M., et al. 8,11-dihydroksy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug resistant cell lines. Synthesis and antitumor evaluation. J. Med. Chem. 42:1999;3494-3501
20. Tkaczyk-Gobis K., Tarasiuk J., Seksek O., et al. Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells. Eur J. Pharmacol. 413:2001;131-141
21. 1,4-di(4-coumaroyl)spermines. Helv. Chim. Acta. 81:1998;2270-2281
22. Bernier J.L., Hénichart J.P. Convenient and general method for the preparation of tert-butoxycarbonylaminoalkanenitriles and their conversion to tert-butoxycarbonyl-alkanediamines. Synthesis. 1:1998;259-261
23. Daehne W.V., Frederiksen E., Gundersen E., et al. Acyloxymethyl esters of ampicilin. J. Med. Chem. 13:1970;607-612
24. Ulich L.H., Adams R. The reaction between acid halides and aldehydes III. J. Am. Soc. 43:1921;660-667
25. Oszczapowicz I, Sikora A, Borowicz P, et al. Sposób izolacji bromku 1-acetoksyetylowego. Zgłoszenie patentowe (Polish Patent Application) nr P 332717, 1999.
26. Kaliszan R, Chromatografia i Techniki Pokrewne w Chemii Środowiska. Dział Wydawnictw UMK Toruń, Poland, Ed. Buszewski B. 1994, p. 64-77.
27. Kaliszan R., Nasal A., Bucinski A. Chromatographic hydrophobicity parameter determined on an immobilized artificial membrane column: relationships to standard measures of hydrophobicity and bioactivity. Eur. J. Med. Chem. 29:1994;163-170
28. Ong S., Liu H., Pidgeon C.H. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J. Chromatogr. A. 728:1996;113
29. Morgan A.R., Lee J.S., Pulleyblank D.E., et al. Review. Ethidium fluorescence assays. Part 1. Physicochemical studies. Nucl. Acids Res. 7:1979;547-569
30. Lozzio C.B., Lozzio R.B. Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome. Blood. 45:1975;321-334
31. McGrath T., Latoud C., Arnold S.T., et al. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 38:1989;3611-3619
32. Marsh W., Sicheri D., Center M.S. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res. 46:1986;4053-4057
33. Zijlstra J.G., de Vries E.G.E., Mulder N.H. Multifactorial drug resistance in adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47:1987;1780-1784
34. Tarasiuk J., Frezard F., Garnier-Suillerot A., et al. Anthracycline incorporation in human lymphocytes: kinetics of uptake and nuclear concentration. Biochim. Biophys. Acta. 1013:1989;109-117
35. Frezard F., Garnier-Suillerot A. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells. Biochim. Biophys. Acta. 1091:1991;29-35
36. Frezard F., Garnier-Suillerot A. Comparison of membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J. Biochem. 196:1991;483-491
37. Mankhetkorn S., Dubru F., Hesschenbrouck J., et al. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein- mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug resistant K562 cells. Mol. Pharmacol. 49:1996;532-539
38. Marbeuf-Gueye C., Broxterman H.J., Dubru F., et al. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol. Pharmacol. 53:1998;141-147
39. Lowry O.H., Rosebrough N.J., Far A.L., et al. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275
40. Schacterle G.R., Pollack R.L. A simplified method for the quantitative assay of small amounts of protein in biological material. Anal. Biochem. 51:1973;654-655
41. 3-4-metoxyfumaroyl-L-2,3-diaminopropanoic acid, an antifungal agent, on mammalian cells in tissue culture. Acta Biochim. Polon. 38:1991;229-239